37404 Federal Register / Vol. 63, No. 132 / Friday, July 10, 1998 / Notices

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

Direct Comments to OMB

Written comments and/or suggestions

regarding the items contained in this

notice, especially regarding the

estimated public burden and associated

response time, should be directed to the:

Office of Management and Budget,

Office of Regulatory Affairs, New

Executive Office Building, Room 10235,

Washington, D.C. 20503, Attention:

Desk Officer for NIH. To request more

information on the proposed project or

to obtain a copy of the data collection

plans and instruments, contact: Charles

MacKay, Ph.D., NIH Project Clearance

Officer, Division of Grants Policy, Office

of Policy for Extramural Research

Administration, OER, NIH, Rockledge II,

Rm. 2196, 6701 Rockledge Dr.,

Bethesda, MD 20892–7730, or call nontoll free at (301) 435–0978 or E-mail

your request, including your address to:

mackayc@odrockm1.od.nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

August 10, 1998.

Dated: June 30, 1998.

Diana Jaeger,

Director, Division of Grants Policy, Office of

Policy for Extramural Research

Administration, OER, NIH.

[FR Doc. 98–18321 Filed 7–9–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in section 552b(c)(4)

and 552b(c)(6), Title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel, Clinical

Trials Musculoskeletal.

Date: August 3, 1998.

Time: 10:00 a.m. to 1:00 p.m.

Place: To review and evaluate grant

applications.

Place: Natcher Bldg., 45 Center Drive,

Room 5AS25N, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: John R. Lymangrover,

Scientific Review Administrator, NIAMS, 45

Center Drive, Room 5AS 25, Bethesda, MD

20892–650, (301) 594–4952.

Name of Committee: National Institute of

Arthritis and Musculoskeletal and Skin

Diseases Special Emphasis Panel,

Osteoporosis Center.

Date: August 10, 1998.

Time: 10 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant

applications.

Place: Natcher Bldg., 45 Center Drive,

Room 5AS25N, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: John R. Lymangrover,

Scientific Review Administrator, NIAMS, 45

Center Drive, Room 5AS 25, Bethesda, MD

20892–650, (301) 594–4952.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.846, Arthritis,

Musculoskeletal and Skin Diseases Research,

National Institutes of Health, HHS)

Dated: July 2, 1998.

LaVeen Ponds,

Acting Committee Management Officer, NIH.

[FR Doc. 98–18317 Filed 7–9–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of General Medical

Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

General Medical Sciences Special Emphasis

Panel National Research Service Award.

Date: July 17, 1998.

Time: 9:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: Bruce K. Wetzel, Scientific

Review Administrator, Office of Scientific

Review, NIGMS, Natcher Building, Room

1AS–19, Bethesda, MD 20892, (301) 594–

3907.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.375, Minority Biomedical

Research Support; 93.821, Cell Biology and

Biophysics Research; 93.859, Phamacology,

Physiology, and Biological Chemistry

Research; 93.862, Genetics and

Developmental Biology Research; 93.88,

Minority Access to Research Careers; 93.96,

Special Minority Initiatives, National

Institutes of Health, HHS)

Dated: July 2, 1998.

LaVeen Ponds,

Acting Committee Management Officer, NIH.

[FR Doc. 98–18318 Filed 7–9–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Public Health Service

National Toxicology Program; Notice

of International Workshop to ‘‘Evaluate

Research Needs on the Use and Safety

of Medicinal Herbs’’

The Workshop will be held at the

National Institute of Environmental

Health Sciences, Conference Facility in

Research Triangle Park, North Carolina

September 23 and 24 1998 from 8:30 to

5:00 each day.

Background

Herbal medicines and dietary

supplements account for one of the

fastest growing markets in U.S.

pharmacies and constitute a multibillion dollar industry. It is estimated

that as many as 1,500 botanicals are sold

in the U.S. as dietary supplements or

ethnic traditional medicines. It is

further estimated that greater than 50%

of the U.S. population uses one or more

dietary supplements including

medicinal herbs. Medicinal herbs are

not, however, subject to the same testing

for efficacy or safety mandated for

prescription or over-the-counter drugs.

Given the increasing use of some

medicinal herbs and the paucity of

toxicological data, this workshop will

bring together a panel of national and

international experts to discuss the use

of the medicinal herbs and dietary

supplements and to establish research

needs that address public health